Breast Cancer
Clinical Trials
1) Up to 3 lines of post-adjuvant or neoadjuvant therapy for TNBC/AYALA: AL-TNBC-01: A Phase 2, Multicenter, Open-label study of AL101 Monotherapy in Patients with Notch Activated Recurrent or Metastatic Triple Negative Breast Cancer
2) First line for locally advanced/ metastatic ER+ HER2 Neg/ BO41843: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GD9545 Combined with Palbociclib Compared with Letrozole Combined with Palbociclib in Patients with ER+, HER2 Neg Locally Advanced or Metastatic Breast Cancer
3) First and Second line of therapy (dependent upon monotherapy or combination therapy/Zeno 001: A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination with Palbociclib in Subjects with Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer.
4) First line advanced/metastatic ER+ HER2 Neg ZENO 003 (ON HOLD): A Phase 1B Study of ZN-c5 in Combination with Abemaciclib in Patients with Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
5) WO42633: A Phase 3, Randomized, Double Blind, Placebo Controlled Clinical Trail To Evaluate The Efficacy And Safety Of Adjuvant Atezolizumab OR Placebo And Trastuzumab Emtansine For HER2-Postive Breast Cancer At High Risk Of Recurrence Following Preoperative Therapy.
6) eMonoarch I3Y-MC-JPCW USO#20364: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in patients with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2 Targeted Therapy
Send UsA Message
The Power of a United Breast Cancer Team: Your Leading Breast Cancer Allies
From diagnosis to treatment and follow-ups, Charleston Oncology, as a part of the Department of Bon Secours St. Francis’ leading multidisciplinary cancer care team, plays a vital role in guiding patients through their breast cancer journey.
Celebrating Strength and Hope: Join Us for the 6th Annual Pink Promenade
Celebrating Strength and Hope: Join Us for the 6th Annual Pink Promenade Mount Pleasant Towne Centre is thrilled to announce our 6th Annual Pink Promenade Breast Cancer Awareness Fundraiser, an event that embodies hope, strength, and resilience. Scheduled for...
Jenny’s Journey Reflects Our Mission
At Charleston Oncology, the mission of healing all people with compassion, faith and excellence resonates through the hallways and translates into every patient interaction.
Myra Walks in a Patient’s Shoes
In the busy corridors of Charleston Oncology on a triple-booked day of patients, a moment of pure human kindness unfolded, illustrating what it truly means to walk in a patient’s shoes.
March is National Colorectal Cancer Awareness Month
March is Colorectal Cancer Awareness Month. This month, Charleston Oncology recognizes the importance of spreading awareness surrounding the disease.
Empowering Health: Charleston Oncology Observes National Cancer Prevention Month
Empowering Health: Charleston Oncology Observes National Cancer Prevention Month Every year in the United States, nearly 1.9 million people (about twice the population of South Dakota) face the life-altering diagnosis of cancer, according to the National Institutes of...
